AHA.13: Special reports on tap

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
 - Dallas

The American Heart Association (AHA) will present 19 special reports in addition to late-breaking clinical trials Nov. 17-19 at its scientific sessions in Dallas. The special reports are listed below.

  • Mechanisms of Bone Marrow Derived Cell Therapy in Ischemic Cardiomyopathy with Left Ventricular Assist Device (LVAD) Bridge to Transplant
  • Assessment of Safety and Efficacy of Autologous Mesenchymal Stem Cells and Whole Bone Marrow in Patients with Ischemic Cardiomyopathy: The TAC-HFT Trial
  • Intramyocardial Injection of Allogeneic Mesenchymal Precursor Cells in Left Ventricular Assist Device Patients
  • The NHLBI TIME Trial, one-year safety and efficacy results from a randomized double-blind placebo study
  • Safety and Efficacy of Sitagliptin Plus Granulocyte-colony Stimulating Factor in Patients Suffering from Acute Myocardial Infarction – Sitagrami Trial
  • Effect of Progenitor Cell Mobilization with Granulocyte Macrophage Colony Stimulating Factor in Patients with Peripheral Artery Disease and Claudication; GPAD-II, a Phase II randomized trial
  • Repetitive Intra-arterial Infusion of Bone Marrow-derived Mononuclear Cells In Patients With No-option Critical Limb Ischemia, a randomized, double-blind, placebo-controlled clinical trial
  • Flow Reserve (FFR) At Time of Diagnostic Angiography: Insights from a Large French Multicenter FFR Registry (R3F)
  • CPT1A Methylation is a Novel Epigenetic Marker of Cardiovascular Risk: Genetic of Lipid Lowering Drugs and Diet Network (GOLDN)
  • 10-Year Incidence Rates of Major Cardiovascular Events in 697,690 Immigrants to Ontario, Canada, by Ethnic Group and Country of Birth, part of the Cardiovascular Health in Ambulatory Care Research Team (CANHEART) project
  • China Rural Health Initiative – Primary Care Provider Study: A Large Cluster-Randomized Controlled Trial of High Cardiovascular Risk Management in Rural China
  • Does Aspirin Intake at Bedtime Decrease Blood Pressure and Morning Peak of Platelet Reactivity? ASPIRETENSION II, a randomized cross-over trial
  • Daylight: Vitamin D Therapy In Individuals At High Risk Of Hypertension
  • Effect of Angiotensin II Type I Receptor Blockade on Carotid Artery Atherosclerosis: A Randomized Trial Comparing Valsartan and Placebo (EFFERVESCENT)
  • Randomized Comparison of the Safety, Tolerability and Efficacy of Long-term Administration of AMG 145 Versus Standard of Care in 1,104 Patients: 52-week Results from the OSLER Study, a study involving patients receiving treatment for hypercholesterolemia
  • The Incidence of Kidney Injury for Patients Treated with Intensive Versus Less Potent Statin Therapy after an Acute Coronary Syndrome
  • First-in-Man Clinical Evaluation of a Novel Tissue Engineered Vascular Graft, a preclinical trial
  • Dedicated ICD Programming Reduces the Number Of Inappropriate Therapies in a Real World Primary Prevention ICD Population: The DECREASE Trial
  • A Multicenter, Randomized Study Assessing the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Advanced Heart Failure Patients with Ischemic and Nonischemic Cardiomyopathy: Interim Results of the AUGMENT-HF Study